Literature DB >> 21983688

The influence of distributional kinetics into a peripheral compartment on the pharmacokinetics of substrate partitioning between blood and brain tissue.

Jeannie M Padowski1, Gary M Pollack.   

Abstract

Development of CNS-targeted agents often focuses on identifying compounds with "good" CNS exposure (brain-to-blood partitioning >1). Some compounds undergoing enterohepatic recycling (ER) evidence a partition coefficient, K (p,brain) (expressed as C (brain) /C (plasma)), that exceeds and then decreases to (i.e., overshoots) a plateau (distribution equilibrium) value, rather than increasing monotonically to this value. This study tested the hypothesis that overshoot in K (p,brain) is due to substrate residence in a peripheral compartment. Simulations were based on a 3-compartment model with distributional clearances between central and brain (CL (br)) and central and peripheral (CL (d)) compartments and irreversible clearance from the central compartment (CL). Parameters were varied to investigate the relationship between overshoot and peripheral compartment volume (V (p)), and how this relationship was modulated by other model parameters. Overshoot magnitude and duration were characterized as peak C (brain)/C (plasma) relative to the plateau value (%OS) and time to reach plateau (TRP). Except for systems with high CL (d), increasing V (p) increased TRP and %OS. Increasing brain (V (br)) or central (V (c)) distribution volumes eliminated V (p)-related OS. Parallel increases in all clearances shortened TRP, but did not alter %OS. Increasing either CL or CL (d) individually increased %OS related to V (p), while increasing CL (br) decreased %OS. Under realistic peripheral distribution scenarios, C (brain)/C (plasma) may overshoot substantially K (p,brain) at distribution equilibrium. This observation suggests potential for erroneous assessment of brain disposition, particularly for compounds which exhibit a large apparent V (p), and emphasizes the need for complete understanding of distributional kinetics when evaluating brain uptake.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983688     DOI: 10.1007/s10928-011-9218-0

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  31 in total

Review 1.  Challenges for blood-brain barrier (BBB) screening.

Authors:  P Jeffrey; S G Summerfield
Journal:  Xenobiotica       Date:  2007 Oct-Nov       Impact factor: 1.908

Review 2.  Physiology and pharmacological role of the blood-brain barrier.

Authors:  Jacek Bernacki; Aleksandra Dobrowolska; Katarzyna Nierwińska; Andrzej Małecki
Journal:  Pharmacol Rep       Date:  2008 Sep-Oct       Impact factor: 3.024

Review 3.  Addressing central nervous system (CNS) penetration in drug discovery: basics and implications of the evolving new concept.

Authors:  Andreas Reichel
Journal:  Chem Biodivers       Date:  2009-11       Impact factor: 2.408

4.  Effect of mode of administration on drug distribution in a two-compartment open system.

Authors:  M Gibaldi
Journal:  J Pharm Sci       Date:  1969-03       Impact factor: 3.534

5.  Assessment of drug absorption after oral administration.

Authors:  K K Chan; M Gibaldi
Journal:  J Pharm Sci       Date:  1985-04       Impact factor: 3.534

6.  Physiologic and metabolic influences on enterohepatic recirculation: simulations based upon the disposition of valproic acid in the rat.

Authors:  G M Pollack; K L Brouwer
Journal:  J Pharmacokinet Biopharm       Date:  1991-04

7.  Pharmacokinetics and pharmacodynamics of valproate analogs in rats. II. Pharmacokinetics of octanoic acid, cyclohexanecarboxylic acid, and 1-methyl-1-cyclohexanecarboxylic acid.

Authors:  M J Liu; G M Pollack
Journal:  Biopharm Drug Dispos       Date:  1993-05       Impact factor: 1.627

Review 8.  Progress in brain penetration evaluation in drug discovery and development.

Authors:  Xingrong Liu; Cuiping Chen; Bill J Smith
Journal:  J Pharmacol Exp Ther       Date:  2008-01-18       Impact factor: 4.030

Review 9.  Drug targeting to the brain.

Authors:  William M Pardridge
Journal:  Pharm Res       Date:  2007-06-07       Impact factor: 4.200

10.  Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates.

Authors:  Stacie L Stapleton; Patrick A Thompson; Ching-Nan Ou; Stacey L Berg; Leticia McGuffey; Brian Gibson; Susan M Blaney
Journal:  Cancer Chemother Pharmacol       Date:  2007-05-31       Impact factor: 3.333

View more
  2 in total

1.  Influence of enterohepatic recycling on the time course of brain-to-blood partitioning of valproic acid in rats.

Authors:  Jeannie M Padowski; Gary M Pollack
Journal:  Drug Metab Dispos       Date:  2012-06-19       Impact factor: 3.922

2.  Enteric reabsorption processes and their impact on drug pharmacokinetics.

Authors:  Manuel Ibarra; Iñaki F Trocóniz; Pietro Fagiolino
Journal:  Sci Rep       Date:  2021-03-11       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.